Freedom of Information

1. How many Haemophilia A patients are registered with your centre?

2. How many of these patients are classified as exhibiting mild, moderate or severe disease?

3. In the last 3 months (April, May, and June 2023), how many Haemophilia A patients were treated with the following coagulation factors:

a. Hemlibra (standalone)
b. Hemlibra (in combination with any FVIII product)
c. Advate
d. Adynovi
e. Elocta
f. Esperoct
g. NovoEight
h. ReFacto AF
i. Nuwiq
j. NovoSeven
k. FEIBA
l. Obizur

4. In the year (January 2022 to June 2023), how many total Hemophilia A inhibitor patients were treated at your centre?

a. Of these, how many had major surgery?
b. If any, what type of major surgery did they have?
c. How many had minor surgeries?
d. How many had more than one surgery?
e. Which coagulation factor brands (NovoSeven, Hemlibra, Obizur, FEIBA, or other) were they treated with?

5. What volume of coagulation factor (in IU or mg) was distributed to East Kent Hospitals University NHS Foundation Trust each month for April, May, and June 2023, broken down by product (see below). If the volume by brand is not available, I would like to request the number of vials distributed by brand

a. Hemlibra
b. Esperoct
c. Adynovi
d. Elocta
e. NovoEight
f. Advate
g. ReFacto AF
h. Nuwiq
i. NovoSeven
j. FEIBA
k. Obizur
l. Idelvion
m. Refixia
n. Alprolix
o. BeneFIX
p. Replenine
q. Rixubis
r. Voncento
s. Veyvondi
t. Wilate
u. Willfact